#United States #Chicago #oncology #Akeso #Ivonescimab

As excitement builds for the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Akeso, Inc. has announced that it will present over 40 clinical studies related to its pioneering oncology portfolio. Scheduled for May 29 to June 2 in Chicago, Illinois, this event is poised to highlight Akeso's commitment to advancing cancer treatment through innovative therapies. Among the most anticipated highlights is the presentation of pivotal data on ivonescimab, a first-in-class bispecific antibody targeting PD-1 and VEGF. This data, stemming from the Phase III HARMONi-6 study, will showcase the overall survival benefits of ivonescimab in combination with chemotherapy compared to traditional PD-1 inhibitors alongside chemotherapy for patients with advanced squamous non-small cell lung cancer (sq-NSCLC). The inclusion of this late-breaking abstract in the prestigious plenary session further emphasizes the impact of Akeso's contributions to oncology. In addition to the major presentation, attendees can expect four other oral or rapid oral presentations elucidating the efficacy of ivonescimab across various settings. For instance, findings related to ivonescimab's effect in small-cell lung cancer (SCLC) after first-line chemoimmunotherapy, as well as its use in first-line metastatic colorectal cancer (mCRC), will capture significant attention from the oncology community. The breadth and depth of these presentations reflect Akeso's innovative spirit in cancer treatment and its mission to develop therapies that could reshape current practice methods across a multitude of cancers. The company will also present research surrounding cadonilimab, another leading bispecific antibody from its portfolio. Studies indicating the effectiveness of cadonilimab-based regimens in multiple cancer types, including renal cell carcinoma, melanoma, and gynecological malignancies, will further bolster Akeso's position as an innovative leader in biopharmaceuticals. Akeso's robust research and development pipeline, leveraging advanced platforms such as their Tetrabody antibody and AI-driven drug discovery technologies, underscores their commitment to delivering first-in-class therapies. The findings presented at ASCO 2026 are a testament to efforts that not only aim to advance scientific understanding but also seek to address unmet medical needs in oncology. All eyes will be on ASCO 2026 as Akeso unveils crucial data that may influence future treatment paradigms and improve outcomes for cancer patients globally.